 | • レポートコード：MRC2Q12-19124 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、イブリツモマブチウキセタンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 イブリツモマブチウキセタンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 イブリツモマブチウキセタンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 イブリツモマブチウキセタンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのイブリツモマブチウキセタンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のイブリツモマブチウキセタンの売上および2028年までの予測に焦点を当てています。 イブリツモマブチウキセタンのグローバル主要企業には、CASI Pharmaceuticals、Biogen、Bayer、Spectrum、CSL Behring、Grifols、Baxalta、Octapharma、Kedrionなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 イブリツモマブチウキセタン市場は、タイプとアプリケーションによって区分されます。世界のイブリツモマブチウキセタン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 0.05、0.25 【アプリケーション別セグメント】 濾胞性非ホジキンリンパ腫、転移性B細胞非ホジキンリンパ腫 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - イブリツモマブチウキセタン製品概要 - タイプ別市場（0.05、0.25） - アプリケーション別市場（濾胞性非ホジキンリンパ腫、転移性B細胞非ホジキンリンパ腫） - 調査の目的 ・エグゼクティブサマリー - 世界のイブリツモマブチウキセタン販売量予測2017-2028 - 世界のイブリツモマブチウキセタン売上予測2017-2028 - イブリツモマブチウキセタンの地域別販売量 - イブリツモマブチウキセタンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別イブリツモマブチウキセタン販売量 - 主要メーカー別イブリツモマブチウキセタン売上 - 主要メーカー別イブリツモマブチウキセタン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（0.05、0.25） - イブリツモマブチウキセタンのタイプ別販売量 - イブリツモマブチウキセタンのタイプ別売上 - イブリツモマブチウキセタンのタイプ別価格 ・アプリケーション別市場規模（濾胞性非ホジキンリンパ腫、転移性B細胞非ホジキンリンパ腫） - イブリツモマブチウキセタンのアプリケーション別販売量 - イブリツモマブチウキセタンのアプリケーション別売上 - イブリツモマブチウキセタンのアプリケーション別価格 ・北米市場 - 北米のイブリツモマブチウキセタン市場規模（タイプ別、アプリケーション別） - 主要国別のイブリツモマブチウキセタン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのイブリツモマブチウキセタン市場規模（タイプ別、アプリケーション別） - 主要国別のイブリツモマブチウキセタン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のイブリツモマブチウキセタン市場規模（タイプ別、アプリケーション別） - 主要国別のイブリツモマブチウキセタン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のイブリツモマブチウキセタン市場規模（タイプ別、アプリケーション別） - 主要国別のイブリツモマブチウキセタン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのイブリツモマブチウキセタン市場規模（タイプ別、アプリケーション別） - 主要国別のイブリツモマブチウキセタン市場規模（トルコ、サウジアラビア） ・企業情報 CASI Pharmaceuticals、Biogen、Bayer、Spectrum、CSL Behring、Grifols、Baxalta、Octapharma、Kedrion ・産業チェーン及び販売チャネル分析 - イブリツモマブチウキセタンの産業チェーン分析 - イブリツモマブチウキセタンの原材料 - イブリツモマブチウキセタンの生産プロセス - イブリツモマブチウキセタンの販売及びマーケティング - イブリツモマブチウキセタンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - イブリツモマブチウキセタンの産業動向 - イブリツモマブチウキセタンのマーケットドライバー - イブリツモマブチウキセタンの課題 - イブリツモマブチウキセタンの阻害要因 ・主な調査結果 |
It is the world’s first radiolabeled monoclonal antibody, launched in the United States in 2002 and approved for the treatment of refractory and relapsed B-cell non-Hodgkin’s lymphoma. Radioimmunization represented by Zevalin marks a new era for human treatment of non-Hodgkin lymphoma. Zevalin combines the excellent targeting of monoclonal antibodies and the powerful radiotherapy effect of radioisotopes, so it can maximize the effect of radiotherapy. kill tumor cells.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Ibritumomab Tiuxetan estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Ibritumomab Tiuxetan include CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma and Kedrion, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Ibritumomab Tiuxetan companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Ibritumomab Tiuxetan market. Further, it explains the major drivers and regional dynamics of the global Ibritumomab Tiuxetan market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
CASI Pharmaceuticals
Biogen
Bayer
Spectrum
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Market Segments
This report has explored the key segments: by Concentration and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by concentration and by application segments based on value for the period 2017-2028.
Ibritumomab Tiuxetan Segment by Concentration
0.05
0.25
Ibritumomab Tiuxetan Segment by Application
Follicular Non-hodgkin Lymphoma
Metastatic B-cell Non-hodgkin Lymphoma
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Ibritumomab Tiuxetan market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Ibritumomab Tiuxetan market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Ibritumomab Tiuxetan, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Ibritumomab Tiuxetan, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Ibritumomab Tiuxetan revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Ibritumomab Tiuxetan market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Ibritumomab Tiuxetan revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma and Kedrion, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Ibritumomab Tiuxetan in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ibritumomab Tiuxetan companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by concentration, by application and by country, revenue for each segment.
Chapter 7: Europe by concentration, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by concentration, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by concentration, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by concentration, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ibritumomab Tiuxetan revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Concentration
1.2.1 Global Ibritumomab Tiuxetan Market Size Growth Rate by Concentration, 2017 VS 2021 VS 2028
1.2.2 0.05
1.2.3 0.25
1.3 Market by Application
1.3.1 Global Ibritumomab Tiuxetan Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Follicular Non-hodgkin Lymphoma
1.3.3 Metastatic B-cell Non-hodgkin Lymphoma
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ibritumomab Tiuxetan Market Perspective (2017-2028)
2.2 Ibritumomab Tiuxetan Growth Trends by Region
2.2.1 Ibritumomab Tiuxetan Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Ibritumomab Tiuxetan Historic Market Size by Region (2017-2022)
2.2.3 Ibritumomab Tiuxetan Forecasted Market Size by Region (2023-2028)
2.3 Ibritumomab Tiuxetan Market Dynamics
2.3.1 Ibritumomab Tiuxetan Industry Trends
2.3.2 Ibritumomab Tiuxetan Market Drivers
2.3.3 Ibritumomab Tiuxetan Market Challenges
2.3.4 Ibritumomab Tiuxetan Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ibritumomab Tiuxetan Players by Revenue
3.1.1 Global Top Ibritumomab Tiuxetan Players by Revenue (2017-2022)
3.1.2 Global Ibritumomab Tiuxetan Revenue Market Share by Players (2017-2022)
3.2 Global Ibritumomab Tiuxetan Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ibritumomab Tiuxetan Revenue
3.4 Global Ibritumomab Tiuxetan Market Concentration Ratio
3.4.1 Global Ibritumomab Tiuxetan Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ibritumomab Tiuxetan Revenue in 2021
3.5 Ibritumomab Tiuxetan Key Players Head office and Area Served
3.6 Key Players Ibritumomab Tiuxetan Product Solution and Service
3.7 Date of Enter into Ibritumomab Tiuxetan Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ibritumomab Tiuxetan Breakdown Data by Concentration
4.1 Global Ibritumomab Tiuxetan Historic Market Size by Concentration (2017-2022)
4.2 Global Ibritumomab Tiuxetan Forecasted Market Size by Concentration (2023-2028)
5 Ibritumomab Tiuxetan Breakdown Data by Application
5.1 Global Ibritumomab Tiuxetan Historic Market Size by Application (2017-2022)
5.2 Global Ibritumomab Tiuxetan Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Ibritumomab Tiuxetan Market Size (2017-2028)
6.2 North America Ibritumomab Tiuxetan Market Size by Concentration
6.2.1 North America Ibritumomab Tiuxetan Market Size by Concentration (2017-2022)
6.2.2 North America Ibritumomab Tiuxetan Market Size by Concentration (2023-2028)
6.2.3 North America Ibritumomab Tiuxetan Market Share by Concentration (2017-2028)
6.3 North America Ibritumomab Tiuxetan Market Size by Application
6.3.1 North America Ibritumomab Tiuxetan Market Size by Application (2017-2022)
6.3.2 North America Ibritumomab Tiuxetan Market Size by Application (2023-2028)
6.3.3 North America Ibritumomab Tiuxetan Market Share by Application (2017-2028)
6.4 North America Ibritumomab Tiuxetan Market Size by Country
6.4.1 North America Ibritumomab Tiuxetan Market Size by Country (2017-2022)
6.4.2 North America Ibritumomab Tiuxetan Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Ibritumomab Tiuxetan Market Size (2017-2028)
7.2 Europe Ibritumomab Tiuxetan Market Size by Concentration
7.2.1 Europe Ibritumomab Tiuxetan Market Size by Concentration (2017-2022)
7.2.2 Europe Ibritumomab Tiuxetan Market Size by Concentration (2023-2028)
7.2.3 Europe Ibritumomab Tiuxetan Market Share by Concentration (2017-2028)
7.3 Europe Ibritumomab Tiuxetan Market Size by Application
7.3.1 Europe Ibritumomab Tiuxetan Market Size by Application (2017-2022)
7.3.2 Europe Ibritumomab Tiuxetan Market Size by Application (2023-2028)
7.3.3 Europe Ibritumomab Tiuxetan Market Share by Application (2017-2028)
7.4 Europe Ibritumomab Tiuxetan Market Size by Country
7.4.1 Europe Ibritumomab Tiuxetan Market Size by Country (2017-2022)
7.4.2 Europe Ibritumomab Tiuxetan Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ibritumomab Tiuxetan Market Size (2017-2028)
8.2 Asia-Pacific Ibritumomab Tiuxetan Market Size by Concentration
8.2.1 Asia-Pacific Ibritumomab Tiuxetan Market Size by Concentration (2017-2022)
8.2.2 Asia-Pacific Ibritumomab Tiuxetan Market Size by Concentration (2023-2028)
8.2.3 Asia-Pacific Ibritumomab Tiuxetan Market Share by Concentration (2017-2028)
8.3 Asia-Pacific Ibritumomab Tiuxetan Market Size by Application
8.3.1 Asia-Pacific Ibritumomab Tiuxetan Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Ibritumomab Tiuxetan Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Ibritumomab Tiuxetan Market Share by Application (2017-2028)
8.4 Asia-Pacific Ibritumomab Tiuxetan Market Size by Region
8.4.1 Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Ibritumomab Tiuxetan Market Size (2017-2028)
9.2 Latin America Ibritumomab Tiuxetan Market Size by Concentration
9.2.1 Latin America Ibritumomab Tiuxetan Market Size by Concentration (2017-2022)
9.2.2 Latin America Ibritumomab Tiuxetan Market Size by Concentration (2023-2028)
9.2.3 Latin America Ibritumomab Tiuxetan Market Share by Concentration (2017-2028)
9.3 Latin America Ibritumomab Tiuxetan Market Size by Application
9.3.1 Latin America Ibritumomab Tiuxetan Market Size by Application (2017-2022)
9.3.2 Latin America Ibritumomab Tiuxetan Market Size by Application (2023-2028)
9.3.3 Latin America Ibritumomab Tiuxetan Market Share by Application (2017-2028)
9.4 Latin America Ibritumomab Tiuxetan Market Size by Country
9.4.1 Latin America Ibritumomab Tiuxetan Market Size by Country (2017-2022)
9.4.2 Latin America Ibritumomab Tiuxetan Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ibritumomab Tiuxetan Market Size (2017-2028)
10.2 Middle East & Africa Ibritumomab Tiuxetan Market Size by Concentration
10.2.1 Middle East & Africa Ibritumomab Tiuxetan Market Size by Concentration (2017-2022)
10.2.2 Middle East & Africa Ibritumomab Tiuxetan Market Size by Concentration (2023-2028)
10.2.3 Middle East & Africa Ibritumomab Tiuxetan Market Share by Concentration (2017-2028)
10.3 Middle East & Africa Ibritumomab Tiuxetan Market Size by Application
10.3.1 Middle East & Africa Ibritumomab Tiuxetan Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Ibritumomab Tiuxetan Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Ibritumomab Tiuxetan Market Share by Application (2017-2028)
10.4 Middle East & Africa Ibritumomab Tiuxetan Market Size by Country
10.4.1 Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 CASI Pharmaceuticals
11.1.1 CASI Pharmaceuticals Company Details
11.1.2 CASI Pharmaceuticals Business Overview
11.1.3 CASI Pharmaceuticals Ibritumomab Tiuxetan Introduction
11.1.4 CASI Pharmaceuticals Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.1.5 CASI Pharmaceuticals Recent Developments
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Ibritumomab Tiuxetan Introduction
11.2.4 Biogen Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.2.5 Biogen Recent Developments
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Ibritumomab Tiuxetan Introduction
11.3.4 Bayer Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.3.5 Bayer Recent Developments
11.4 Spectrum
11.4.1 Spectrum Company Details
11.4.2 Spectrum Business Overview
11.4.3 Spectrum Ibritumomab Tiuxetan Introduction
11.4.4 Spectrum Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.4.5 Spectrum Recent Developments
11.5 CSL Behring
11.5.1 CSL Behring Company Details
11.5.2 CSL Behring Business Overview
11.5.3 CSL Behring Ibritumomab Tiuxetan Introduction
11.5.4 CSL Behring Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.5.5 CSL Behring Recent Developments
11.6 Grifols
11.6.1 Grifols Company Details
11.6.2 Grifols Business Overview
11.6.3 Grifols Ibritumomab Tiuxetan Introduction
11.6.4 Grifols Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.6.5 Grifols Recent Developments
11.7 Baxalta
11.7.1 Baxalta Company Details
11.7.2 Baxalta Business Overview
11.7.3 Baxalta Ibritumomab Tiuxetan Introduction
11.7.4 Baxalta Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.7.5 Baxalta Recent Developments
11.8 Octapharma
11.8.1 Octapharma Company Details
11.8.2 Octapharma Business Overview
11.8.3 Octapharma Ibritumomab Tiuxetan Introduction
11.8.4 Octapharma Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.8.5 Octapharma Recent Developments
11.9 Kedrion
11.9.1 Kedrion Company Details
11.9.2 Kedrion Business Overview
11.9.3 Kedrion Ibritumomab Tiuxetan Introduction
11.9.4 Kedrion Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.9.5 Kedrion Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer